RxDoctor Payments Data

Johnny Thomas, DO

Internal Medicine · Jackson Heights, NYNPI 1619906047

Payments from drug & device makers

$2,691in general payments, 2019–2025

Across 109 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$779
  • AstraZeneca$392
  • Exact Sciences$243
  • Novo Nordisk$242
  • Otsuka America Pharmaceutical, Inc.$205
  • Amgen$174
  • plus $656 from 11 others

What the payments were for

  • Food & beverage$2,57596%
  • Education$1164%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,691 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$26,424
Medicare patients
65
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol56$35,061
JardianceEmpagliflozin50$32,488
EntrestoSacubitril/Valsartan34$22,263
TrulicityDulaglutide18$16,551
KerendiaFinerenone22$14,901
JanuviaSitagliptin Phosphate15$14,726
RybelsusSemaglutide13$12,279
OzempicSemaglutide11$9,824
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,417
Spiriva RespimatTiotropium Bromide13$6,473
Incruse ElliptaUmeclidinium Bromide15$5,041
EliquisApixaban12$4,777
VascepaIcosapent Ethyl14$4,644
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp18$3,301
Albuterol Sulfate HfaAlbuterol Sulfate95$3,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$392$45,89180 claims
Boehringer IngelheimJardiance, Spiriva Respimat$39$38,96063 claims
Novo NordiskRybelsus, Ozempic$242$22,10324 claims
Lilly USA, LLCTrulicity$119$16,55118 claims
BayerKerendia$779$14,90122 claims
PfizerEliquis$59$4,77712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jackson Heights

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →